BRCA1 and cancer: The activity of PARPi in certain cancers with deficient homologous recombination repair ability (mainly due to BRCA1/2 mutations) was the first clinical demonstration of the role of exploiting HR alterations to improve outcomes and prolong survival in cancer patients.